OXYGEN
20/05/2005, 16h03
Single injection could replace implant for drug delivery
Nanotechnology to revolutionise drug delivery: Silicon delivery system improves therapy of liver cancer
19/05/2005 - A single injection could replace implants for some drugs that require continuous administration, according to preliminary experiments with a novel drug delivery technology, reports Phil Taylor.
The delivery vehicle, called BioSilicon and developed by nanotechnology company pSivida, BioSilicon’s porous nanostructure effectively stores an active compound in tiny pockets that release minute amounts of drug as the silicon dissolves.
The study, performed by pSivida in collaboration with Australian company EpiTan, compared four BioSilicon formulations containing the tanning agent Melanotan (alpha-melanocyte stimulating hormone) to EpiTan’s implantable formulation, currently in clinical development.
Melanotan is designed to promote the formation of the skin pigment melanin in the skin without exposure to ultraviolet light, and thereby protect fair-skinned people in sunny climates from developing skin cancer. Previously the drug has been delivered as a daily injection that required significantly higher quantities. As with any pharmacological agent, it is preferable to limit the amount delivered to reduce the risk of side effects
http://www.in-pharmatechnologist.com/news/ng.asp?n=60097&m=1IPE519&c=fqxuoqfzsiywdyn
NDLR : Les peaux blanches vont pouvoir bronzer et être protégées du soleil !
Nanotechnology to revolutionise drug delivery: Silicon delivery system improves therapy of liver cancer
19/05/2005 - A single injection could replace implants for some drugs that require continuous administration, according to preliminary experiments with a novel drug delivery technology, reports Phil Taylor.
The delivery vehicle, called BioSilicon and developed by nanotechnology company pSivida, BioSilicon’s porous nanostructure effectively stores an active compound in tiny pockets that release minute amounts of drug as the silicon dissolves.
The study, performed by pSivida in collaboration with Australian company EpiTan, compared four BioSilicon formulations containing the tanning agent Melanotan (alpha-melanocyte stimulating hormone) to EpiTan’s implantable formulation, currently in clinical development.
Melanotan is designed to promote the formation of the skin pigment melanin in the skin without exposure to ultraviolet light, and thereby protect fair-skinned people in sunny climates from developing skin cancer. Previously the drug has been delivered as a daily injection that required significantly higher quantities. As with any pharmacological agent, it is preferable to limit the amount delivered to reduce the risk of side effects
http://www.in-pharmatechnologist.com/news/ng.asp?n=60097&m=1IPE519&c=fqxuoqfzsiywdyn
NDLR : Les peaux blanches vont pouvoir bronzer et être protégées du soleil !